Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir + PegIFN/RBV in Japanese HCV Patients
NCT01579474Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Started Apr 2012; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01579474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01579474.